320 related articles for article (PubMed ID: 11695559)
1. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens.
French J; Storer RD; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():24-9. PubMed ID: 11695559
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of potential human carcinogens using B6.129tm1Trp53 heterozygous null mice and loss of heterozygosity at the Trp53 locus.
French JE
IARC Sci Publ; 2004; (157):271-87. PubMed ID: 15055301
[TBL] [Abstract][Full Text] [Related]
3. Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent.
French JE; Lacks GD; Trempus C; Dunnick JK; Foley J; Mahler J; Tice RR; Tennant RW
Carcinogenesis; 2001 Jan; 22(1):99-106. PubMed ID: 11159747
[TBL] [Abstract][Full Text] [Related]
4. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing.
Venkatachalam S; Tyner SD; Pickering CR; Boley S; Recio L; French JE; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():147-54. PubMed ID: 11695551
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 11 allelotypes reflect a mechanism of chemical carcinogenesis in heterozygous p53-deficient mice.
Hulla JE; French JE; Dunnick JK
Carcinogenesis; 2001 Jan; 22(1):89-98. PubMed ID: 11159746
[TBL] [Abstract][Full Text] [Related]
6. P53+/- hemizygous knockout mouse: overview of available data.
Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
[TBL] [Abstract][Full Text] [Related]
7. DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: nature of the models.
van Steeg H; de Vries A; van Oostrom CTh ; van Benthem J; Beems RB; van Kreijl CF
Toxicol Pathol; 2001; 29 Suppl():109-16. PubMed ID: 11695546
[TBL] [Abstract][Full Text] [Related]
8. Xpa and Xpa/p53+/- knockout mice: overview of available data.
van Kreijl CF; McAnulty PA; Beems RB; Vynckier A; van Steeg H; Fransson-Steen R; Alden CL; Forster R; van der Laan JW; Vandenberghe J
Toxicol Pathol; 2001; 29 Suppl():117-27. PubMed ID: 11695547
[TBL] [Abstract][Full Text] [Related]
9. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
Cohen SM
Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
[TBL] [Abstract][Full Text] [Related]
10. Neonatal mouse model: review of methods and results.
McClain RM; Keller D; Casciano D; Fu P; MacDonald J; Popp J; Sagartz J
Toxicol Pathol; 2001; 29 Suppl():128-37. PubMed ID: 11695548
[TBL] [Abstract][Full Text] [Related]
11. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
12. Detection of genotoxic and non-genotoxic carcinogens in Xpc(-/-)p53(+/-) mice.
Melis JP; Speksnijder EN; Kuiper RV; Salvatori DC; Schaap MM; Maas S; Robinson J; Verhoef A; van Benthem J; Luijten M; van Steeg H
Toxicol Appl Pharmacol; 2013 Jan; 266(2):289-97. PubMed ID: 23153559
[TBL] [Abstract][Full Text] [Related]
13. 1,3-butadiene: cancer, mutations, and adducts. Part III: In vivo mutation of the endogenous hprt genes of mice and rats by 1,3-butadiene and its metabolites.
Walker VE; Meng Q
Res Rep Health Eff Inst; 2000 Mar; (92):89-139; discussion 141-9. PubMed ID: 10925840
[TBL] [Abstract][Full Text] [Related]
14. The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens.
Eastin WC; Haseman JK; Mahler JF; Bucher JR
Toxicol Pathol; 1998; 26(4):461-73. PubMed ID: 9715504
[TBL] [Abstract][Full Text] [Related]
15. CB6F1-rasH2 mouse: overview of available data.
Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
[TBL] [Abstract][Full Text] [Related]
16. Comparison of target organs of carcinogenicity for mutagenic and non-mutagenic chemicals.
Gold LS; Slone TH; Stern BR; Bernstein L
Mutat Res; 1993 Mar; 286(1):75-100. PubMed ID: 7678909
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and carcinogenicity studies of chlorpromazine hydrochloride and p-cresidine in the p53 heterozygous mouse model.
Petruska JM; Frank DW; Freeman GB; Evans EW; MacDonald JS
Toxicol Pathol; 2002; 30(6):696-704. PubMed ID: 12512871
[TBL] [Abstract][Full Text] [Related]
18. Genetically altered mouse models for identifying carcinogens.
Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
[No Abstract] [Full Text] [Related]
19. Lack of susceptibility of heterozygous p53-knockout CBA and CIEA mice to phenolphthalein in a 6-month carcinogenicity study.
Okamura M; Kashida Y; Watanabe T; Yasuhara K; Onodera H; Hirose M; Usui T; Tamaoki N; Mitsumori K
Toxicology; 2003 Mar; 185(1-2):17-22. PubMed ID: 12505441
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of hormonal carcinogenesis in the p53+/- hemizygous knockout mouse: studies with diethylstilbestrol.
Carmichael PL; Mills JJ; Campbell M; Basu M; Caldwell J
Toxicol Pathol; 2001; 29 Suppl():155-60. PubMed ID: 11695552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
